We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Normal Tension and Chronic Open Angle Glaucoma and Cerebrospinal Fluid Composition

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified April 2007 by Kantonsspital Aarau.
Recruitment status was:  Recruiting
Sponsor:
ClinicalTrials.gov Identifier:
NCT00306657
First Posted: March 24, 2006
Last Update Posted: June 27, 2011
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Kantonsspital Aarau
  Purpose
Normal tension glaucoma (NTG) and chronic open angle glaucoma (COAG) occurring progressively with optimal conventional or intraocular pressure reducing surgery are still unsolved problems in ophthalmology. The investigators would like to investigate whether or not the composition of cerebrospinal fluid (CSF) surrounding the optic nerve (ON) in these patients is pathologic under certain conditions. They therefore compare the CSF taken during optic nerve sheath fenestration with the CSF taken during a lumbar puncture. The investigators' hypothesis is that, in patients with NTG and COAG, the composition of CSF surrounding the affected ON plays an important role in promoting progressive visual function loss.

Condition Intervention
Glaucoma Open-Angle Procedure: Optic nerve sheath fenestration

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Normal Tension and Chronic Open Angle Glaucoma, Cerebrospinal Fluid Composition in Subarachnoid Space of Affected Optic Nerves

Resource links provided by NLM:


Further study details as provided by Kantonsspital Aarau:

Primary Outcome Measures:
  • Visual acuity
  • Visual field
  • Quality of life assessment
  • Laboratory markers work-up

Estimated Enrollment: 30
Study Start Date: March 2006
Estimated Study Completion Date: December 2012
Detailed Description:
We will recruit 30 patients with progressive visual function loss, due to Normal tension glaucoma (NTG) or chronic open angle glaucoma (COAG), despite optimal conventional or intraocular pressure reducing surgery treatment so far. We will proceed with an optic nerve sheath fenestration (ONSF) (according to the studies in the literature, e.g. Wax MB, Barrett DA, Hart WM Jr, Custer PL. Optic nerve sheath decompression for glaucomatous optic neuropathy with normal intraocular pressure. Arch Ophthalmol. 1993;111(9):1219-28.) and compare the cerebrospinal fluid (CSF) taken from the subarachnoid space (SAS) of the optic nerve (ON) with the CSF taken during a lumbar puncture, on the same day. Concentrations of neurobioactive substances will especially be studied. Visual acuity and visual field development before and after ONSF will be studied. Quality of life assessment will be done before and several times after ONSF.
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Documented progressive visual function loss over 2 years (visual field or visual acuity)
  • Intraocular pressure measured as a maximum of 25 mmHg
  • Possibility of receiving general anaesthesia and optic nerve sheath fenestration.

Exclusion Criteria:

  • Secondary glaucoma
  • Oral medication to lower intraocular pressure (carboanhydrase inhibitor)
  • Visual acuity worse than 20/400
  • Any other type of glaucoma (pseudoexfoliation, narrow or closed angle).
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00306657


Contacts
Contact: Hanspeter E Killer, MD, Prof +41628385021 killer@ksa.ch
Contact: Gregor P Jaggi, MD +41763261306 gregor.jaggi@gmx.ch

Locations
Switzerland
Kantonsspital Aarau, Department of Ophthalmology, Switzerland Recruiting
Aarau, Aargau, Switzerland, 5001
Contact: Hanspeter E Killer, MD, Prof    +41628385021    killer@ksa.ch   
Contact: Gregor P Jaggi, MD    +41763261306    gregor.jaggi@gmx.ch   
Principal Investigator: Hanspeter E Killer, MD Prof         
Sponsors and Collaborators
Kantonsspital Aarau
Investigators
Principal Investigator: Hanspeter E Killer, MD, Prof Kantonsspital Aarau, Department of ophthalmology
  More Information

Additional Information:
Publications:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
ClinicalTrials.gov Identifier: NCT00306657     History of Changes
Other Study ID Numbers: 2005/057
First Submitted: March 23, 2006
First Posted: March 24, 2006
Last Update Posted: June 27, 2011
Last Verified: April 2007

Keywords provided by Kantonsspital Aarau:
Glaucoma Open-Angle
Normal tension glaucoma progressive
chronic open angle glaucoma progressive
optic nerve sheath fenestration
cerebrospinal fluid
Beta-Trace Protein

Additional relevant MeSH terms:
Glaucoma
Glaucoma, Open-Angle
Ocular Hypertension
Eye Diseases